Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Ribo Life Science CoHKSE:06938 -4.07%9 Gross Margin % is 84.60% as of Dec. 2025, which is 7% below its 10-year median of 90.93. GuruFocus rates HKSE:06938 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 737 Biotechnology companies, Suzhou Ribo Life Science Co ranks better than 92.27% on this metric.
Suzhou Ribo Life Science Co (HKSE:06938) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Suzhou Ribo Life Science Co had a gross margin of 84.60% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Suzhou Ribo Life Science Co Gross Margin % Related Terms
Suzhou Ribo Life Science Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06938 vs VRTX, REGN, MRNA: Gross Margin % Comparison
For the Biotechnology subindustry, Suzhou Ribo Life Science Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Ribo Life Science Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Ribo Life Science Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Suzhou Ribo Life Science Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Suzhou Ribo Life Science Co (HKSE:06938) has a Gross Margin % of 84.60% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Suzhou Ribo Life Science Co and its competitors. This is near median its historical median of 90.93. Over the past decade, Suzhou Ribo Life Science Co's Gross Margin % has ranged from 45.83 to 94.46. According to the industry distribution chart, Suzhou Ribo Life Science Co ranks #57 out of 737 companies in the Biotechnology industry, placing it in the top 7.7%.
Is Suzhou Ribo Life Science Co's Gross Margin % too high?
Suzhou Ribo Life Science Co's current Gross Margin % of 84.60% is near median its 10-year median of 90.93. Over the past 10 years, this metric has ranged from a low of 45.83 to a high of 94.46. The Biotechnology industry median Gross Margin % is 60.91. Suzhou Ribo Life Science Co's value of 84.60% is 38.9% above this industry median. Based on the distribution chart, Suzhou Ribo Life Science Co ranks #57 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Suzhou Ribo Life Science Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Suzhou Ribo Life Science Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Ribo Life Science Co ranks #57 out of 737 companies for Gross Margin %. This places Suzhou Ribo Life Science Co in the top 8% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Suzhou Ribo Life Science Co's value of 84.60% is 38.9% above this benchmark. Historically, Suzhou Ribo Life Science Co's own Gross Margin % has ranged from 45.83 to 94.46 over the past decade. While the company's 10-year median is 90.93 vs. the industry median of 60.91, Suzhou Ribo Life Science Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Ribo Life Science Co's current Gross Margin % of 84.60% is 38.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Suzhou Ribo Life Science Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Ribo Life Science Co's current Gross Margin % is 84.60%, which is near median its own 10-year median of 90.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Ribo Life Science Co stock overvalued right now?
Suzhou Ribo Life Science Co (HKSE:06938) has a current Gross Margin % of 84.60%. The current Gross Margin % is 84.60%, which is near median its 10-year median of 90.93 and 38.9% above the Biotechnology industry median of 60.91. Suzhou Ribo Life Science Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Suzhou Ribo Life Science Co (HKSE:06938), the current Gross Margin % is 84.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Suzhou Ribo Life Science Co Ltd is a biopharmaceutical company engaged in oligonucleotide R&D, with a focus on siRNA therapeutics. The company's pipeline focuses on cardiovascular, metabolic, renal and liver diseases. Its pipeline includes RBD4059, RBD5044, RBD7007, RBD1119, RBD3103, SR122, SR126, RBD1016, SR112/SR113, among others. It has one reportable operating segment.
9GF Score
Get the complete analysis for HKSE:06938
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06938 has been successfully added to your 
